Femasys Overview
DCF fair value estimate for Femasys: $-0.18.
Get informed when a big investor buys or sells
+ Follow$-0.18
Overvalued by 107.5% based on the discounted cash flow analysis.
Femasys (FEMY) currently reports a DCF fair value of $-0.18. Use the charts on this page to explore Femasys's DCF fair value history and peer comparisons.
Femasys's discounted cash flow (DCF) fair value estimate is $-0.18, about 107.5% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-0.18, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Femasys, and consider following FEMY for alerts when major investors trade the stock.
Femasys is classified in the Healthcare sector. On DCF fair value, it currently shows $-0.18. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FEMY with unrelated industries.
